Bristol Glucovance Has 1.5% Share; 60% Of Patients Are New To Metformin
Executive Summary
Bristol-Myers Squibb's metformin/glyburide combination product Glucovance has a 1.5% share of the diabetes market one month after launch, Bristol told securities analysts Sept. 28 in New York City.
You may also be interested in...
Glucophage XR Generics Will Be Early Test Of Bristol/FTC Settlement
The expiration of marketing exclusivity forGlucophage XR will provide an early test of the impact of Bristol-Myers Squibb's settlement with the Federal Trade Commission over Bristol's aggressive patent defense tactics
Glucophage XR Generics Will Be Early Test Of Bristol/FTC Settlement
The expiration of marketing exclusivity forGlucophage XR will provide an early test of the impact of Bristol-Myers Squibb's settlement with the Federal Trade Commission over Bristol's aggressive patent defense tactics
Bristol Repositions Glucovance, Glucophage XR As Metformin Generics Loom
A money-back guarantee will be part of Bristol-Myers Squibb's repositioning efforts for the metformin line extensions Glucophage XR and Glucovance.